A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

NCT05306340 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

373

Enrollment

INDUSTRY

Sponsor class

Conditions

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Interventions

DRUG: Giredestrant
DRUG: Exemestane
DRUG: Fulvestrant
DRUG: Tamoxifen
DRUG: Everolimus
DRUG: LHRH Agonist
DRUG: Dexamethasone Mouth Rinse

Sponsor

Genentech, Inc.